Multi-omic ADNI CSF and plasma data integration identifies distinct metabolic transitions in disease progression in Alzheimer's Disease

Tom Paterson,Jennifer Rohrs,Timothy J Hohman,Mark Mapstone,Allan I Levey,LeRoy Hood,Cory C Funk

DOI: https://doi.org/10.1101/2024.07.23.604835

2024-07-24

Abstract:Age and APOE allele status are the two greatest risk factors for Alzheimer's disease, with microglial processing, recycling of debris and cholesterol transport emerging as other key genetic determinants from AD GWAS. How risk factors contribute to neuronal loss is an unanswered question. Using the ADNI dataset, we provide evidence for distinct processes driving neurodegeneration in AD across a range of ADAS13 scores binned into quartiles (Q1-4) found in ADNI. In Q1 individuals, we see evidence of white matter hyperintensities (WMH) associated with complement and HDL proteins, independent of tau and hippocampal atrophy rates. In Q2 individuals, we see specific protein/lipid correlation networks that are associated with tau and hippocampal atrophy. Also in Q2, we see variations in enzyme levels (LPA2G7, LPCAT2) that impact phosphatidylcholine availability for cholesterol efflux onto CNS lipoproteins. Low LPA2G7 and high LPCAT are associated with lower disruption of ANLS, while high LPA2G7 and low LPCAT are associated with higher disruption. In Q3 individuals, DHA and plasmalogens appear to be protective of astrogliosis, presumably by decreasing lipid droplet size, and increasing their lipid debris flux capacity. The networks we identify in this analysis provide evidence that progressively elevated cellular cholesterol levels, likely the result of accelerating neuronal and myelin debris, are perturbing homeostatic processes, resulting in disruption of astrocyte-neuron lactate shuttle (ANLS), contributing to lipid droplet formation, and astrogliosis. Existing studies have already identified elevated cellular cholesterol as the driver of increased access of APP to β- and γ-secretase for β-amyloid production in late-onset AD. Importantly, we provide evidence that points to actionable variations in lipids associated with slower disease progression and decreased metabolic disruption and inflammation. We believe this positive feedback loop (neurodegeneration → lipid debris processing → metabolic disruption → neurodegeneration) is a key destabilizing cycle responsible for disease progression in AD, reinforcing the perspective that Alzheimer's is fundamentally a metabolic disease. Our findings are consistent with established lipid risk factor associations. We anticipate the mechanistic insights from our analysis will advance nutritional and pharmacological interventions and slow cognitive decline.

Neuroscience

What problem does this paper attempt to address?

This paper attempts to address the issue of different metabolic transitions during the pathological progression of Alzheimer's disease (AD). Specifically, using the ADNI dataset, the researchers explored how specific metabolic processes drive neurodegeneration in different stages of Alzheimer's disease (divided into four quartiles Q1 - Q4 according to the ADAS13 score) by integrating multi - omics data (including proteomics and lipidomics data in cerebrospinal fluid and plasma). The research focused on the following aspects:

1. **The relationship between white matter hyperintensities (WMH) and complement and HDL proteins**: In cognitively normal individuals (Q1), the study found that WMH was related to complement and HDL proteins, but independent of tau protein levels and hippocampal atrophy rates.

2. **The relationship between specific protein/lipid - related networks and tau protein and hippocampal atrophy**: In individuals with mild cognitive impairment (MCI) (Q2), specific protein/lipid - related networks were observed to be related to tau protein and hippocampal atrophy. In addition, changes in enzyme levels (such as LPA2G7 and LPCAT2) were also found, which affect the availability of phosphatidylcholine and, in turn, the efflux of cholesterol from lipoproteins in the central nervous system.

3. **The protective effect of DHA and Plasmalogens on astrocyte proliferation**: In individuals with moderate cognitive impairment (Q3), DHA and Plasmalogens are considered to protect astrocytes from damage by reducing lipid droplet size and increasing the ability of lipid fragment flux.

4. **The positive feedback loop between neurodegeneration and lipid metabolism dysregulation**: The study proposed a positive feedback loop model, that is, neurodegeneration leads to an increase in lipid fragment processing, which in turn causes metabolic disorders and ultimately exacerbates neurodegeneration. This loop is considered one of the key mechanisms in the progression of Alzheimer's disease.

5. **The association between lipid metabolism and neurodegeneration**: The study provided evidence that changes in certain lipids are associated with slower disease progression and less metabolic disorder and inflammation. These findings support the view that Alzheimer's disease is a metabolic disease and provide a new perspective for future nutritional and drug interventions.

In summary, through multi - omics data analysis, this paper revealed the changes in specific metabolic processes in different stages of Alzheimer's disease and their impact on disease progression, providing important clues for further understanding the pathological mechanism of Alzheimer's disease and developing new treatment strategies.